[go: up one dir, main page]

EP0756869A2 - Utilisation de la duloxétine ou de N-alkyl-3-phényl-(2-alkylthiophénoxy)-propylamines pour le traitement des troubles de l'attention et de l'hyperactivité - Google Patents

Utilisation de la duloxétine ou de N-alkyl-3-phényl-(2-alkylthiophénoxy)-propylamines pour le traitement des troubles de l'attention et de l'hyperactivité Download PDF

Info

Publication number
EP0756869A2
EP0756869A2 EP96305346A EP96305346A EP0756869A2 EP 0756869 A2 EP0756869 A2 EP 0756869A2 EP 96305346 A EP96305346 A EP 96305346A EP 96305346 A EP96305346 A EP 96305346A EP 0756869 A2 EP0756869 A2 EP 0756869A2
Authority
EP
European Patent Office
Prior art keywords
deficit
disorder
duloxetine
hyperactivity disorder
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96305346A
Other languages
German (de)
English (en)
Other versions
EP0756869A3 (fr
Inventor
John Harrison Heiligenstein
Bennett Coleman Laguzza
Steven Marc Paul
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525909.9A external-priority patent/GB9525909D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0756869A2 publication Critical patent/EP0756869A2/fr
Publication of EP0756869A3 publication Critical patent/EP0756869A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Definitions

  • the invention belongs to the fields of pharmaceutical chemistry and psychiatric medicine, and provides a method of treatment of the psychiatric disorder known as attention-deficit/hyperactivity disorder.
  • Methylphenidate has been used for some time to treat such children and it often significantly improves their ability to function and coexist with other people at school and at home.
  • the drug has the disadvantages of requiring several doses per day, and producing a rebound effect as the effect of each dose fades away. Further, the drug causes sleeplessness and lack of appetite in some patients. Methylphenidate has both noradrenergic and dopaminergic activities.
  • Imipramine, desipramine, nortriptyline, amitriptyline and clomipramine are also used in some cases of attention-deficit/hyperactivity disorder (ADHD) .
  • ADHD attention-deficit/hyperactivity disorder
  • Those tricyclic drugs have a number of physiological mechanisms and, as a class, tend to produce a number of side effects and require careful supervision and dose titration.
  • ADHD is not only a disorder of childhood, but often continues in the adult. It is obvious that hyperactivity and short attention span cause grave disruption in an adult's life, but it is only recently that such patients have been able to obtain any treatment.
  • Duloxetine N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, is usually administered as the hydrochloride salt and as the (+) enantiomer. It was first taught by U.S. Patent 4,956,388, which shows its high potency. The word “duloxetine” will be used here to refer to any acid addition salt or the free base of the molecule.
  • the compounds of formula I were described in U.S. Patent 5,281,624, of Gehlert, Robertson and Wong, and in Gehlert, et al., Life Sciences , 56(22) , 1915-1920, 1995.
  • the compounds are there taught to be inhibitors of norepinephrine reuptake in the brain. It is also explained that the compounds exist as stereoisomers, and that they accordingly include not only the racemates, but also the isolated individual isomers.
  • the compounds of formula I include the following exemplary species.
  • the compounds used in this invention are safe drugs, and their use in ADHD, in both adults and children, is a superior treatment for that disorder because of their improved safety.
  • the compounds are particularly selective, having few if any physiological effects besides that on norepinephrine processing, and therefore are free of side effects and unwanted activities. Further, they are effective at relatively low doses, as discussed below, and may safely and effectively be administered once per day. Thus, difficulties created by the multiple dosing of patients, who are children and disorganized adults, are completely avoided.
  • the present invention is described as a method of treating ADHD. It is not intended, of course, that every use of the invention will result in a complete cure of the disorder. Treatment of psychiatric disorders is not that precise. It is intended, however, that the use of the invention will result in improvement of the treated ADHD patient which will approach complete cure in some cases. In other cases, a lesser degree of improvement, still benefiting the patient, will be obtained. Such treatment is carried out by administering an effective amount of the chosen compound. It will be understood that amount is an amount which produces treatment of the patient at hand.
  • the effective dose of a compound of this invention for ADHD is in the range from about 1 mg/day to about 100 mg/day.
  • the preferred adult dose is in the range from about 5 to about 80 mg/day, and a more highly preferred adult dose is from about 10 to about 60 mg/day.
  • the children's dose of course is smaller, in the range from about 1 to about 70 mg/day, more preferably from about 5 to about 60 mg/day and still more preferably from about 5 to about 50 mg/day.
  • the optimum dose for each patient must be set by the physician in charge of the case, taking into account the patient's size, other medications which the patient requires, severity of the disorder and all of the other circumstances of the patient.
  • the compounds are readily orally absorbed and require only once/day administration, there is little or no reason to administer them in any other way than orally. They may be produced in the form of a clean, stable crystal, and thus are easily formulated in the usual oral pharmaceutical forms, such as tablets, capsules, suspensions, and the like.
  • oral pharmaceutical forms such as tablets, capsules, suspensions, and the like.
  • the usual methods of pharmaceutical scientists are applicable. They may usefully be administered, if there is any reason to do so in a particular circumstance, in other pharmaceutical forms, such as injectable solutions, depot injections, suppositories and the like, which are well known to and understood by pharmaceutical scientists. It will substantially always be preferred, however, to administer a compound as a tablet or capsule and such pharmaceutical forms are recommended.
  • a preferred duloxetine enteric formulation is a pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient; d) an optional finishing layer.
  • HPMCAS hydroxypropylmethylcellulose acetate succinate
  • the duloxetine layer was built up by suspending duloxetine in a 4% w/w solution of the hydroxypropylmethylcellulose in water, and milling the suspension with a CoBall Mill (Fryma Mashinen AG, Rheinfelden, Switzerland) model MS-12. A fluid bed dryer with a Wurster column was used to make this product, at a batch size of 1.0 kg. The separating layer was added from a 4% w/w solution of the hydroxypropylmethylcellulose in water, in which the sucrose was also dissolved.
  • the enteric coating suspension In order to prepare the enteric coating suspension, purified water was cooled to 10°C and the polysorbate, triethyl citrate and silicone emulsion were added and dispersed or dissolved. Then the HPMCAS and talc were added and agitated until homogeneity was obtained, and the HPMCAS was fully neutralized by addition of ammonium hydroxide until solution of the polymer was complete. To this suspension, a carboxymethylcellulose aqueous solution, 0.5% w/w, was added and blended thoroughly. The enteric suspension was maintained at 20°C during the coating process. The enteric suspension was then added to the partially completed pellets in the Wurster column at a spray rate of about 15 ml/min, holding the temperature of the inlet air at about 50°C.
  • the product was dried in the Wurster at 50°C when the enteric suspension had been fully added, and then dried on trays for 3 hours in a dry house at 60°C.
  • a finishing layer was then applied which consisted of a 4.5% w/w/ hydroxypropylmethylcellulose solution containing titanium dioxide and propylene glycol as plasticizer.
  • the pellets were completely dried in the fluid bed dryer and then were then filled in size 3 gelatin capsules.
  • the ADHD patient is rather readily recognized, and most people have been in contact with children, if not adults, who exhibit some or all of the symptoms of the disorder.
  • the best description of the disorder is the diagnostic criteria for ADHD, published by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Version (1994), as follows.
  • ADHD is a disorder made up of two components, the attention deficit component and the hyperactivity component, which are to a degree independent. Treatment with the compounds is effective in patients who are primarily suffering from either component or from the combined disorder.
  • the method of the present invention is effective in the treatment of patients who are children, adolescents or adults, and there is no significant difference in the symptoms or the details of the manner of treatment among patients of different ages.
  • a child is considered to be a patient below the age of puberty
  • an adolescent is considered to be a patient from the age of puberty up to about 18 years of age
  • an adult is considered to be a patient of 18 years or older.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP96305346A 1995-07-24 1996-07-22 Utilisation de la duloxétine ou de N-alkyl-3-phényl-(2-alkylthiophénoxy)-propylamines pour le traitement des troubles de l'attention et de l'hyperactivité Withdrawn EP0756869A3 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US137395P 1995-07-24 1995-07-24
US1373 1995-07-24
US1373P 1995-07-24
US634995P 1995-11-08 1995-11-08
US6349 1995-11-08
US6349P 1995-11-08
GBGB9525909.9A GB9525909D0 (en) 1995-12-19 1995-12-19 Treatment of attention-defecit/hyperactivity disorder
GB9525909 1995-12-19

Publications (2)

Publication Number Publication Date
EP0756869A2 true EP0756869A2 (fr) 1997-02-05
EP0756869A3 EP0756869A3 (fr) 1999-06-16

Family

ID=27268037

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96305346A Withdrawn EP0756869A3 (fr) 1995-07-24 1996-07-22 Utilisation de la duloxétine ou de N-alkyl-3-phényl-(2-alkylthiophénoxy)-propylamines pour le traitement des troubles de l'attention et de l'hyperactivité

Country Status (14)

Country Link
EP (1) EP0756869A3 (fr)
JP (1) JPH11510143A (fr)
KR (1) KR19990035817A (fr)
CN (1) CN1195287A (fr)
AU (1) AU709704B2 (fr)
CA (1) CA2227410A1 (fr)
CZ (1) CZ16798A3 (fr)
EA (1) EA000856B1 (fr)
IL (1) IL122984A0 (fr)
MX (1) MX9800589A (fr)
NO (1) NO980251L (fr)
NZ (1) NZ313076A (fr)
WO (1) WO1997003665A1 (fr)
YU (1) YU43996A (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909561A3 (fr) * 1997-09-23 1999-05-06 Eli Lilly And Company Utilisation de la réboxétine pour le traitement du trouble de déficit de l'attention/hyperactivité
EP0919236A1 (fr) * 1997-09-23 1999-06-02 Eli Lilly And Company Utilisation d'un inhibiteur d'assimilation de norépinéphrine pour le traitement de trouble oppositionel provocant
EP0919235A1 (fr) * 1997-09-23 1999-06-02 Eli Lilly And Company Utilisation d'un inhibiteur d'assimilation de norépinéphrine pour le traitement de trouble de la conduite
WO1999052531A1 (fr) * 1998-04-09 1999-10-21 Pharmacia & Upjohn Company Nouveaux traitements pour troubles nerveux
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
WO2004018441A1 (fr) * 2002-08-23 2004-03-04 Eli Lilly And Company Derives de morpholine arylee et heteroarylee
WO2004103356A3 (fr) * 2003-05-15 2005-03-31 Lilly Co Eli Traitement du dysfonctionnement emotionnel
WO2005021095A3 (fr) * 2003-08-27 2005-06-09 Lilly Co Eli Traitement de begaiement et d'autres troubles de la communication au moyen d'inhibiteurs du recaptage de la noradrenaline
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
IL288712B2 (en) 2015-03-06 2024-01-01 Auspex Pharmaceuticals Inc Methods for the treatment of abnormal involuntary movement disorders
EP3270920B1 (fr) * 2015-03-20 2020-06-17 Intra-Cellular Therapies, Inc. Composés organiques
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
EP0591581B1 (fr) * 1992-10-08 1995-08-09 Eli Lilly And Company N-Alkyl-3-Phényl-3-(1-Alkylthiophénoxy)propylamine
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909561A3 (fr) * 1997-09-23 1999-05-06 Eli Lilly And Company Utilisation de la réboxétine pour le traitement du trouble de déficit de l'attention/hyperactivité
EP0919236A1 (fr) * 1997-09-23 1999-06-02 Eli Lilly And Company Utilisation d'un inhibiteur d'assimilation de norépinéphrine pour le traitement de trouble oppositionel provocant
EP0919235A1 (fr) * 1997-09-23 1999-06-02 Eli Lilly And Company Utilisation d'un inhibiteur d'assimilation de norépinéphrine pour le traitement de trouble de la conduite
US6046193A (en) * 1997-09-23 2000-04-04 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1999052531A1 (fr) * 1998-04-09 1999-10-21 Pharmacia & Upjohn Company Nouveaux traitements pour troubles nerveux
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
WO2004018441A1 (fr) * 2002-08-23 2004-03-04 Eli Lilly And Company Derives de morpholine arylee et heteroarylee
US7354920B2 (en) 2002-08-23 2008-04-08 Eli Lilly And Company Aryl and heteroaryl morpholine derivatives
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
WO2004103356A3 (fr) * 2003-05-15 2005-03-31 Lilly Co Eli Traitement du dysfonctionnement emotionnel
WO2005021095A3 (fr) * 2003-08-27 2005-06-09 Lilly Co Eli Traitement de begaiement et d'autres troubles de la communication au moyen d'inhibiteurs du recaptage de la noradrenaline
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (fr) 2012-11-14 2020-02-19 The Johns Hopkins University Procédés et compositions de traitement de la schizophrénie
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia

Also Published As

Publication number Publication date
CN1195287A (zh) 1998-10-07
WO1997003665A1 (fr) 1997-02-06
NO980251D0 (no) 1998-01-20
EA000856B1 (ru) 2000-06-26
YU43996A (sh) 1999-06-15
AU6506196A (en) 1997-02-18
CA2227410A1 (fr) 1997-02-06
AU709704B2 (en) 1999-09-02
NO980251L (no) 1998-01-20
IL122984A0 (en) 1998-08-16
CZ16798A3 (cs) 1998-11-11
EP0756869A3 (fr) 1999-06-16
MX9800589A (es) 1998-04-30
NZ313076A (en) 1999-11-29
KR19990035817A (ko) 1999-05-25
EA199800152A1 (ru) 1998-08-27
JPH11510143A (ja) 1999-09-07

Similar Documents

Publication Publication Date Title
EP0721777B1 (fr) Utilisation de tomoxetine pour le traitement de l'hyperactivité induite par les troubles d'attention
US6046193A (en) Treatment of attention-deficit/hyperactivity disorder
AU709704B2 (en) Treatment of attention-deficit/hyperactivity disorder
US6184222B1 (en) Treatment of conduct disorder
AU740109B2 (en) Treatment of oppositional defiant disorder
US5696168A (en) Treatment of attention-deficit/hyperactivity disorder
MXPA98000589A (en) Treatment of disorder of lack of attention / hyperactivi
US4880833A (en) Synergistic pharmaceutical compositions, their production and use
ES2237842T3 (es) Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad.
West et al. Sudden hypotension associated with midazolam and sufentanil
HUP9903171A2 (hu) Duloxetin alkalmazása figyelemcsökkenéssel/hiperaktivitással kapcsolatos rendellenességek kezelésére alkalmas gyógyászati készítmények előállítására
MXPA97005117A (en) Use of tomoxetine for the manufacture of a medicine for the treatment of the disorder of deficitde the attention / hyperactivi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960730

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 960730;LT PAYMENT 960730;LV PAYMENT 960730;SI PAYMENT 960730

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19960730;LT PAYMENT 19960730;LV PAYMENT 19960730;SI PAYMENT 19960730

17Q First examination report despatched

Effective date: 20010831

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021015